Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition-Reference-Cited by-同舟云学术

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

Published:2020-06-17 Issue:7 Volume:12 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Paliouras Athanasios R¹²,Buzzetti Marta¹³,Shi Lei¹²,Donaldson Ian J⁴,Magee Peter¹²,Sahoo Sudhakar⁵,Leong Hui‐Sun⁵,Fassan Matteo⁶,Carter Matthew²⁷,Di Leva Gianpiero⁸,Krebs Matthew G²⁷,Blackhall Fiona²⁷,Lovly Christine M⁹,Garofalo Michela¹²^ORCID

Affiliation:

1. Transcriptional Networks in Lung Cancer Group Cancer Research UK Manchester Institute University of Manchester Manchester UK

2. Cancer Research UK Lung Cancer Centre of Excellence Manchester and University College London London UK

3. Biomedical Research Centre School of Science, Engineering and Environment University of Salford Salford UK

4. Bioinformatics Core Facility Faculty of Biology, Medicine and Health University of Manchester Manchester UK

5. Computational Biology Support Cancer Research UK Manchester Institute University of Manchester Manchester UK

6. Department of Medicine, Surgical Pathology & Cytopathology Unit University of Padua Padua Italy

7. Division of Cancer Sciences Faculty of Biology, Medicine and Health Christie Hospital University of Manchester Manchester UK

8. School of Pharmacy and Bioengineering Guy Hilton Research Institute Keele University Keele UK

9. Vanderbilt‐Ingram Cancer Center Vanderbilt University Medical Center Nashville TN USA

Funder

Cancer Research UK

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201911099

Reference38 articles.

1. Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions

2. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

3. Trimmomatic: a flexible trimmer for Illumina sequence data

4. Acquired resistance to TKIs in solid tumours: learning from lung cancer

5. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and verification of characteristic differentially expressed ferroptosis-related genes in osteosarcoma using bioinformatics analysis;Toxicology Mechanisms and Methods;2023-08-08

2. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries;Molecular Oncology;2023-05-15

3. DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing;GigaScience;2022-12-28

4. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective;Signal Transduction and Targeted Therapy;2022-09-17

5. DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy;Experimental & Molecular Medicine;2022-08-23